Four in 10 patients with plaque psoriasis achieved complete disease clearance with tapinarof cream, 1%, according to a study published in the Journal of the American Academy of Dermatology. Bruce Strober, MD, PhD, and colleagues assessed the long-term safety, efficacy, remittive effect, durability of response, and tolerability of tapinarof for the treatment of mild-to-severe plaque psoriasis. The analysis included 763 patients who completed the 12-week trial and were eligible for 40 weeks of open-label treatment and 4 weeks of follow-up. Among participants, 40.9% achieved complete disease clearance (Physician Global Assessment [PGA] of 0). More than one-half of participants (58.2%) entering with a PGA of at least 2 achieved a PGA of 0 or 1. For patients achieving a PGA of 0, mean duration of remittive effect off-therapy was 130.1 days. No new safety signals were seen. Folliculitis (22.7%), contact dermatitis (5.5%), and upper respiratory tract infection (4.7%) were the most frequent adverse events.
